Today, on 5 July, the Annual Report 2012 and the Corporate Responsibility Report 2012 of the JSC “Grindeks” were submitted to “NASDAQ OMX Riga”.

Chairman of the Board of JSC “Grindeks” Juris Bundulis: “Our basic approach is patient-centred and we consider it to be our major success driver. We care about our patients’ health and this gives our business sufficient motivation to be competitive and effective on the global market. The effectiveness of these efforts was proved by our 2012 yearly financial results, reaching the biggest turnover profit figures over the past five years, realising significant projects in both investments and corporate social responsibility area. More information about the company’s activities is accessible in the Annual Report 2012 and the Corporate Responsibility Report 2012."

About “Grindeks”

"Grindeks" is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of "Grindeks" consists of four subsidiary companies in Latvia, Estonia and Russia, as well as representative offices in 11 countries.

"Grindeks" specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently "Grindeks" produces 24 active pharmaceutical ingredients.

Products of the company are exported to 55 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 45.6 million lats over the years.

JSC "Grindeks" shares are listed on the Official List of “NASDAQ OMX Riga”. Major shareholders of JSC "Grindeks" are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” (nominal holder) – 10.22%, “Swedbank” AS Clients Account (nominal holder) – 8.71%.

More information about the company – www.grindeks.lv/en/

Follow "Grindeks":

Twitter.com/AS_Grindeks; Youtube.com/GrindeksLV 

Further information:

Laila Kļaviņa
Head of the Communications Department, JSC “Grindeks”
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
laila.klavina@grindeks.lv